Scarica l'app Stockscreener
1.48
3.50%
0.05
Dopo l'orario di chiusura:
1.53
0.05
+3.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.43
Aprire:
$1.46
Volume 24 ore:
432.81K
Relative Volume:
0.76
Capitalizzazione di mercato:
$41.62M
Reddito:
$80.97M
Utile/perdita netta:
$-78.31M
Rapporto P/E:
-0.0997
EPS:
-14.85
Flusso di cassa netto:
$-129.56M
1 W Prestazione:
-15.91%
1M Prestazione:
-19.13%
6M Prestazione:
-23.32%
1 anno Prestazione:
-29.19%
Intervallo 1D:
$1.455
$1.54
Intervallo di 1 settimana:
$1.41
$1.75
Portata 52W:
$1.355
$4.43
Fortress Biotech Inc Stock (FBIO) Company Profile
Nome
Fortress Biotech Inc
Settore
Industria
Telefono
781-652-4500
Indirizzo
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Confronta FBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| FBIO | 1.48 | 41.62M | 80.97M | -78.31M | -129.56M | -14.85 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-15 | Ripresa | ROTH MKM | Buy |
| 2022-08-04 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-02 | Iniziato | The Benchmark Company | Buy |
| 2019-12-18 | Iniziato | B. Riley FBR | Buy |
| 2018-02-28 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | Iniziato | Rodman & Renshaw | Buy |
| 2017-03-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-10-03 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Fortress Biotech Inc Borsa (FBIO) Ultime notizie
Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners - TipRanks
Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright - TipRanks
Fortress Biotech (FRA:CNB1) Total Inventories : €9.00 Mil (As of Jun. 2024) - GuruFocus.com
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Fortress Biotech: Q3 Earnings Snapshot - mySA
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy
Fortress Biotech’s Q3 2024 Earnings and FDA Milestone - TipRanks
Fortress Biotech Q3 2024 Earnings: EPS Loss of $0.76 Beats Estimate, Revenue of $14.63M Misses Expectations - GuruFocus.com
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Checkpoint Therapeutics Sets FDA Review Date, Secures $9.2M Funding Boost Amid Q3 Loss | FBIO Stock News - StockTitan
Journey Medical's Mixed Q3: FDA Win for Rosacea Drug Despite Revenue Dip | FBIO Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance - Investing.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan
Where are the Opportunities in (FBIOP) - Stock Traders Daily
Mustang Bio gains FDA Orphan Drug Status for glioma treatment - Investing.com India
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Mustang Bio gains FDA Orphan Drug Status for glioma treatment By Investing.com - Investing.com UK
How To Trade (FBIOP) - Stock Traders Daily
Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry - Simply Wall St
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares - Yahoo Finance
Highbridge Capital Management's Strategic Acquisition of Fortres - GuruFocus.com
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference - GlobeNewswire
Mustang Bio secures $4 million from warrant exercises - Investing.com India
Mustang Bio secures $4 million from warrant exercises By Investing.com - Investing.com South Africa
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds - The Manila Times
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit - The Manila Times
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - GlobeNewswire
Analysts review Fortress Biotech Inc’s rating - Knox Daily
Was there any good news for Fortress Biotech Inc (FBIO) stock in the last session? - US Post News
PRESIDENT, CEO & CHAIRMAN ROSENWALD LINDSAY A MD acquire 763,359 shares of Fortress Biotech Inc [FBIO] - Knox Daily
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
Fortress Biotech Inc (FBIO) expanding its growth trajectory ahead - SETE News
Nantahala Capital Management LLC Sells 125,000 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
PVG Asset Management Corp Invests $266,000 in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Fortress Biotech Inc (FBIO) receives a Buy rating from ROTH MKM - Knox Daily
Fortress Biotech Inc (FBIO)’s results reveal risk - US Post News
Fortress Biotech Inc Azioni (FBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):